Renee N. Donahue - Concepedia

Author

Renee N. Donahue

Also Known As

Donahue, Renee, R. Donahue, R.N. Donahue, Renee N. Donahue, Renee Donahue, Renee N Donahue, Renee N. Donahue, Renee Nicole Donahue

250

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research National Institutes of Health Pennsylvania State University Merck (Germany)

About

Renee N. Donahue is an author at National Cancer Institute specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	33	1.8K
2	Cell Biology	10	11	817
3	Health Sciences	5	5	284
4	Allergy	2	2	84
5	Engineering	1	1	11

Renee N. Donahue

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Clinical Cancer Research	2018	406
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations Fatima Karzai, David James VanderWeele, Ravi A. Madan, Journal for ImmunoTherapy of Cancer	2018	295
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan, The Lancet Oncology MedicineJavelin Solid TumorSolid TumoursMetronomic TherapySurgery	2017	292
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors Marijo Bilušić, Christopher R. Heery, Julie Collins, Journal for ImmunoTherapy of Cancer	2019	256
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine Anna Kwilas, Andressa Ardiani, Renee N. Donahue, Journal of Translational Medicine	2014	185
Effects of conventional therapeutic interventions on the number and function of regulatory T cells Mario Roselli, Vittore Cereda, Maria Giovanna di Bari, OncoImmunology Cell TherapyT-regulatory CellImmunologyImmune RegulationPathology	2013	184
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors Julius Strauss, Christopher R. Heery, Joseph W. Kim, Clinical Cancer Research	2018	164
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho, Journal for ImmunoTherapy of Cancer	2020	153
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue, Journal for ImmunoTherapy of Cancer	2020	143
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells Caroline Jochéms, Massimo Fantini, Romaine I. Fernando, Oncotarget T-regulatory CellImmunologyImmune RegulationImmunoeditingImmunotherapeutics	2016	140

Page 1